WHAT IS CLAIMED IS:

~~1. The use of a compound:~~

~~4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide,~~

~~4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, or~~

~~4-[7-(4-cyano-3-(trifluoromethyl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;~~

~~in the manufacture of a medicament for treating non-metastatic castration-resistant prostate cancer in a male human, wherein the compound is used in combination with orchiectomy.~~

~~2. The use according to claim 1, wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.~~

~~3. The use according to claim 2, wherein the male human with the high risk non-metastatic castration-resistant prostate cancer has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.~~

~~4. The use according to claim 1, wherein administration of the compound provides an increase in the metastasis-free survival of the male human.~~

~~5. The use according to claim 1, wherein the compound is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.~~

~~6. The use according to claim 5, wherein the medicament is for treatment by oral administration of the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide to the male human.~~

~~7. The use according to claim 5, wherein the medicament is for treatment by oral administration of the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide on a continuous daily dosing schedule to the male human.~~

8. The use according to claim 5, wherein the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is present in the medicament in a unit dosage form, wherein the unit dosage form is in the form of a tablet.

9. The use according to claim 5, wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is present in the medicament at a dose of about 30 mg to about 480 mg.

10. The use according to claim 5, wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is present in the medicament at a dose of about 240 mg.

11. The use according to claim 5, wherein 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is present in the medicament in a unit dosage form containing :

(a) about 30 mg;

(b) about 60 mg;

(c) about 90 mg;

(d) about 120 mg;

(e) about 180 mg;

(f) about 240 mg;

(g) about 300 mg;

(h) about 390 mg; or

(i) about 480 mg.

12. The use according to claim 5, wherein the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is present in the medicament in a unit dosage form containing 60 mg of the compound for administration 2, 3 or 4 times per day.

13. The use according to claim 5, wherein the medicament is for treatment by administration of the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide post orchiectomy.

14. The use according to claim 1, wherein the compound is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.

15. The use according to claim 16, wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is present in the medicament at a dose of about 160 mg.

16. The use according to claim 1, wherein the compound is 4-[7-(4-cyano-3-(trifluoromethyl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

17. The use according to claim 14 or 16, wherein the medicament is for treatment by oral administration of the compound to the male human.

18. The use according to claim 14 or 16, wherein the medicament is for treatment by oral administration of the compound on a continuous daily dosing schedule to the male human.

19. The use according to claim 14 or 16, wherein compound is present in the medicament in a unit dosage form, wherein the unit dosage form is in the form of a tablet.

20. The use according to claim 14 or 16, wherein the medicament is for treatment by administration of the compound post orchiectomy.

21. A compound

4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 fluoro-N-methylbenzamide,

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, or

4-[7-(4-cyano-3-(trifluoromethyl)phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide;

for use in a method of treating a male with non-metastatic castration-resistant prostate cancer, wherein the method comprises administering the therapeutically effective amount of the compound to a male human with a non-metastatic castration-resistant prostate cancer in combination with orchiectomy.

WHAT IS CLAIMED IS:

1. The use of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide in the manufacture of a medicament for treating non-metastatic castration-resistant prostate cancer in a male human, wherein the medicament is to be used in combination with a gonadotropin-releasing hormone (GnRH) agonist.

2. The use according to claim 1, wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.

3. The use according to claim 2, wherein the male human with the high risk non-metastatic castration-resistant prostate cancer has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.

4. The use according to claim 1, wherein administration of the medicament provides an increase in the metastasis-free survival of the male human.

5. The use according to claim 1, wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is present in the medicament at a dose of about 160 mg.

6. The use according to claim 1, wherein the medicament is for treatment by oral administration of the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide to the male human.

7. The use according to claim 1, wherein the medicament is for treatment by oral administration of the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide on a continuous daily dosing schedule to the male human.

8. The use according to claim 1, wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is present in the medicament in a unit dosage form, wherein the unit dosage form is in the form of a tablet.

9. The use according to claim 1, wherein the medicament is for administration of the GnRH agonist at a different time as the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.

10. The use according to claim 1, wherein the medicament is for administration of the GnRH agonist at the same time as the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.

11. The use according to claim 1, wherein the male human previously received a first-generation anti-androgen, and wherein the first-generation anti-androgen is bicalutamide, flutamide or nilutamide.

12. The use according to claim 1, wherein the GnRH agonist is leuprolide, buserelin, nafarelin, histrelin, goserelin, or deslorelin.

13. The use according to claim 1, wherein the GnRH agonist is leuprolide.

14. The use according to claim 1, wherein the GnRH agonist is buserelin.

15. The use according to claim 1, wherein the GnRH agonist is nafarelin.

16. The use according to claim 1, wherein the GnRH agonist is histrelin.

17. The use according to claim 1, wherein the GnRH agonist is goserelin.

18. The use according to claim 1, wherein the GnRH agonist is deslorelin.